Off-Label use of Midazolam in randomized controlled trials

Abstract

August 2015 e91 following exposure to this drug. It had also reported that patients who have developed EM during terbinafine treatment suffered from a systemic autoimmune disease and no hepatic disorder was associated to the skin manifestation. Our case was diagnosed to be a suspected case of drug-induced EM with hepatitis on the basis of drug history, clinical presentation, improvement with dechallenge and exclusion of other likely causes of EM and hepatitis. According to the Naranjo probability scale, the adverse drug reaction was considered probable. Conclusion: Clinicians should be aware of the risk of EM associated with terbinafine, a generally well tolerated drug. The skin involvement may be also associated with liver disorder.